Surgical robotic technology developer Stereotaxis (NYSE:STXS) announced that it appointed Nachum “Homi” Shamir to its board of directors.
Shamir most recently served as chair and CEO at Luminex. He held that post from 2014 until the company’s $1.8 billion sale to DiaSorin in 2021.
Before Luminex, Shamir served as president and CEO at Given Imaging. He led the company from 2006 until its sale to Covidien (later acquired by Medtronic) in 2014. Currently, Shamir is the chair of Mediwound, a developer of enzymatic therapeutics for burn and wound care, and Diagnositca, a diagnostics company.
St. Louis-based Stereotaxis said in a news release that he brings significant experience and expertise in growing global commercial organizations. Additionally, the company highlighted his know-how in scaling high-technology medical device operations and executing mergers and acquisitions.
“We are delighted to have Homi join the Stereotaxis Board of Directors,” said David Fischel, chair and CEO. “Stereotaxis is blessed with a Board that brings highly relevant skillsets and complementary expertise as we advance an ambitious strategy. We look forward to benefiting from Homi’s contributions.”
Stereotaxis develops a number of technologies, including the Genesis robotic magnetic navigation (RMN) system. RNM utilizes robotic precision and safety for cardiac ablation. The company also offers the Magic magnetic ablation catheter, which it submitted it for European and U.S. approval in March.
“I am impressed by Stereotaxis’ comprehensive strategy and excited to join the company as it nears significant inflection points,” said Shamir. “I look forward to contributing to the efforts to grow substantial global commercial and operational capabilities, and to the continued refinement of a strategy that will ensure robotics transforms endovascular surgery.”
